About Corcept

Corcept Therapeutics Incorporated (NASDAQ: CORT) is an emerging pharmaceutical company developing medications for the treatment of severe psychiatric and metabolic diseases. Its lead product candidate, CORLUX, modulates the effect of cortisol -- better known as the “stress hormone” -- by selectively blocking the binding of cortisol to one of its two known receptors, the GR-II receptor (also known as the Type II or GR receptor). Corcept has ongoing Phase 3 studies of CORLUX in two indications – Cushing’s Syndrome and psychotic depression;

• Cushing’s Syndrome: The Phase 3 clinical program for Cushing’s Syndrome is due to complete enrollment this year, and data is expected by mid-2010.
• Psychotic Depression: Our Phase 3 clinical program for psychotic depression is actively enrolling patients.
• Next-Generation Selective GR-II Antagonists: Based on positive proof-of-concept data for mitigating antipsychotic-induced weight gain, we plan to file our IND for the lead compound in this series by the end of 2009.  Our plan is to evaluate multiple new indications to establish the broad potential of these selective compounds in regulating cortisol production.

The company retains all rights to commercialize CORLUX and its selective GR-II antagonists. Corcept has exclusively licensed from Stanford University the patent for the use of GR-II antagonists to treat the psychotic features of psychotic depression. The company owns exclusively licensed issued patents and filed patent applications relating to the treatment of multiple disorders also believed to result from, or negatively affected by, prolonged exposure to elevated cortisol (GR-II Antagonist Platform).